Market Overview

UPDATE: JP Morgan Initiates Tenet Healthcare at Overweight on Share Buyback, Reform Leverage

Share:
Related THC
Colorado Cannabis Sales Hit $1.49 Billion In 2017: Taxes Up To $247 Million, Medical Sales Down To $420 Million
Wonder Women Of Weed: Yvonne DeLaRosa Green, The Latina Revolutionizing Conscious Commerce With Cannabis

JP Morgan initiated coverage on Tenet Healthcare (NYSE: THC) with an Overweight rating and a $41 price target.

JP Morgan noted, "While THC stock has performed well of late, we continue to see potential for upside given a combination of strong relative upside from reform in addition to company specific drivers such as accelerating share repurchases, NOL position and Conifer strategy. Our JP Morgan Healthcare Reform Model projects THC is set to see ~10% EBITDA growth, leaving the company behind only LPNT & HCA in terms of reform upside potential in our hospital coverage universe.

Tenet Healthcare closed at $31.18 on Monday.

Latest Ratings for THC

DateFirmActionFromTo
Dec 2017Morgan StanleyDowngradesEqual-WeightUnderweight
Dec 2017JP MorganDowngradesNeutralUnderweight
Dec 2017CitigroupUpgradesNeutralBuy

View More Analyst Ratings for THC
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (THC)

View Comments and Join the Discussion!